ReNeuron to Present

ReNeuron Group plc
12 February 2007


               ReNeuron to Present at 2nd Annual Stem Cell Summit


Guildford, UK, 12 February 2007: ReNeuron Group plc (LSE: RENE.L) today
announces that its Founder and Chief Scientific Officer, Dr. John Sinden, will
present an overview of the Company's leading edge stem cell technologies and
programmes at the 2nd Annual Stem Cell Summit being held at the Wyndham at
Emerald Plaza San Diego in San Diego, California.  The presentation is scheduled
for Monday, February 12, 2007 at 2:45 PM PST.

Utilizing its proprietary c-mycER(TAM) adult stem cell expansion platform,
ReNeuron is developing groundbreaking cell therapy products.  The Company is
currently focused on cell therapy treatments designed to reverse the effects of
major diseases such as stroke, Parkinson's disease, diabetes and diseases of the
retina.

More information about the conference may be found at www.stemcellsummit.com.


Inquiries:

ReNeuron
Michael Hunt, Chief Executive Officer                Tel: [phone]
John Sinden, Chief Scientific Officer

Financial Dynamics
Jonathan Birt                                        Tel: [phone]
Robert Stanislaro                                    Tel: [phone]


Notes to Editors

ReNeuron is a leading, UK-based adult stem cell therapy business. It is applying
its novel stem cell platform technologies in the development of ground-breaking
stem cell therapies to serve significant and unmet or poorly-met clinical needs.
ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines. This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch. Cell growth can therefore be completely arrested prior to in vivo
implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability. This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder. There are an estimated 50 million stroke
survivors worldwide, approximately one half of which are left with permanent
disabilities. The annual health and social costs of caring for these patients is
estimated to be in excess of £5 billion in the UK and in excess of US$50 billion
in the US.

ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem cell
therapy for Huntington's disease, a genetic and fatal neurodegenerative disorder
that affects around 1 in 10,000 people. This programme is in pre-clinical
development.

In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(TM) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry. ReNeuron's ReNcell(TM) CX
and ReNcell(TM) VM neural cell lines are marketed worldwide under license by
Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.


Further information on ReNeuron and its products can be found at
www.reneuron.com.


Data sources: UK Stroke Association, American Stroke Association.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.

The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.




                      This information is provided by RNS
            The company news service from the London Stock Exchange